JP2023528450A5 - - Google Patents

Info

Publication number
JP2023528450A5
JP2023528450A5 JP2022574390A JP2022574390A JP2023528450A5 JP 2023528450 A5 JP2023528450 A5 JP 2023528450A5 JP 2022574390 A JP2022574390 A JP 2022574390A JP 2022574390 A JP2022574390 A JP 2022574390A JP 2023528450 A5 JP2023528450 A5 JP 2023528450A5
Authority
JP
Japan
Prior art keywords
peaks
approximately
theta
degrees
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022574390A
Other languages
English (en)
Japanese (ja)
Other versions
JP7734700B2 (ja
JP2023528450A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/035796 external-priority patent/WO2021247934A1/en
Publication of JP2023528450A publication Critical patent/JP2023528450A/ja
Publication of JP2023528450A5 publication Critical patent/JP2023528450A5/ja
Application granted granted Critical
Publication of JP7734700B2 publication Critical patent/JP7734700B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022574390A 2020-06-04 2021-06-03 ベータアドレナリンアゴニストの形態及び組成物 Active JP7734700B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034900P 2020-06-04 2020-06-04
US63/034,900 2020-06-04
PCT/US2021/035796 WO2021247934A1 (en) 2020-06-04 2021-06-03 Forms and compositions of a beta adrenergic agonist

Publications (3)

Publication Number Publication Date
JP2023528450A JP2023528450A (ja) 2023-07-04
JP2023528450A5 true JP2023528450A5 (cg-RX-API-DMAC7.html) 2024-05-29
JP7734700B2 JP7734700B2 (ja) 2025-09-05

Family

ID=78829944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574390A Active JP7734700B2 (ja) 2020-06-04 2021-06-03 ベータアドレナリンアゴニストの形態及び組成物

Country Status (9)

Country Link
US (1) US20230219892A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161496A4 (cg-RX-API-DMAC7.html)
JP (1) JP7734700B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230021075A (cg-RX-API-DMAC7.html)
CN (1) CN115989019B (cg-RX-API-DMAC7.html)
AU (1) AU2021282582A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179993A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022015165A (cg-RX-API-DMAC7.html)
WO (1) WO2021247934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11607395B2 (en) 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP2023541379A (ja) * 2020-09-01 2023-10-02 キュラセン セラピューティクス インコーポレイテッド 神経系の疾患及び障害を改善するための組成物及び方法
US12616667B2 (en) 2021-11-15 2026-05-05 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN120583945A (zh) 2023-01-20 2025-09-02 阿托基公司 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
WO2003072573A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
WO2011133226A2 (en) 2010-04-22 2011-10-27 The Board Of Trustees Of The Leland Stanford Junior University Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
BR112013012994A2 (pt) * 2010-11-24 2016-09-13 Lithera Inc formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno
US9320724B2 (en) 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
US9889087B2 (en) 2014-06-10 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor
BR112018073227A2 (pt) * 2016-05-13 2019-02-19 The Board Of Trustees Of The Leland Stanford Junior University compostos moduladores do receptor adrenérgico e métodos de uso do mesmo
WO2018169742A1 (en) * 2017-03-14 2018-09-20 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibtor
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
EP3806957A4 (en) * 2018-06-14 2022-03-16 Curasen Therapeutics, Inc. METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
US10947196B2 (en) * 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Similar Documents

Publication Publication Date Title
AU2018349279B2 (en) Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
JP5269349B2 (ja) ベンゾピラン−2−オール誘導体の製造のための方法
JP2011513485A5 (cg-RX-API-DMAC7.html)
JP5377285B2 (ja) キラルアミドおよびキラルアミンの調製
AU2008243132B2 (en) New crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it
JP4575337B2 (ja) アゴメラチンの新規な結晶形態v、その製造方法、およびそれを含有する薬学的組成物
EP2049464A1 (en) Preparation of 3-ý(1r,2r)-3-(dimethylamino)-1ethyl-2-methylpropyl¨phenol
JP2005503386A5 (cg-RX-API-DMAC7.html)
HU228436B1 (en) 6-fluorobicyclo[3.1.0]hexane derivatives
JPH09504024A (ja) 置換2,5−ジアミノ−3−ヒドロキシヘキサンの製造方法
JP2015531403A (ja) ベンズアミド化合物の合成に有用な化合物
TWI725098B (zh) 藉由使用極性非質子性溶劑掌性解析n-[4-(1-胺基乙基)-苯基]-磺醯胺衍生物之方法
CN1216033C (zh) 亚环己基胺的顺式选择性催化氢化方法
CN1288153C (zh) 2-氨基-4-吡啶基甲基-二氢噻唑衍生物作为诱导型no-合酶抑制剂的用途
WO2014111836A1 (en) Process for preparation of fingolimod and its salts
JP2025069143A (ja) tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法
HU227114B1 (en) (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same
CN107445845A (zh) 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1,2‑苯二胺的方法
AU2016327159A1 (en) The process of preparing indoline compounds and a novel indoline salt
WO2005000790A1 (ja) 2-アミノビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体
JP2022539342A5 (cg-RX-API-DMAC7.html)
JPH08509979A (ja) 光学活性な3−(1−(アルキルアミノ))アルキルピロリジン類
WO2018193482A1 (en) Improved method for the synthesis of 1,2-ethanediamine, n, n'-bis(2-aminoethyl)-dihydrochloride(trientine dihydrochloride)
CA2484981A1 (en) 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors
WO2009072062A2 (en) Novel derivatives of dihydroxypyrrolidine as anti-cancer compounds